WO2018167623A1 - Procédé de préparation d'hydrogel antimicrobien - Google Patents
Procédé de préparation d'hydrogel antimicrobien Download PDFInfo
- Publication number
- WO2018167623A1 WO2018167623A1 PCT/IB2018/051586 IB2018051586W WO2018167623A1 WO 2018167623 A1 WO2018167623 A1 WO 2018167623A1 IB 2018051586 W IB2018051586 W IB 2018051586W WO 2018167623 A1 WO2018167623 A1 WO 2018167623A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- silver
- hydrogel
- polyvinyl alcohol
- povidone
- composition
- Prior art date
Links
- 239000000017 hydrogel Substances 0.000 claims abstract description 121
- 229920002451 polyvinyl alcohol Polymers 0.000 claims abstract description 70
- 230000000845 anti-microbial effect Effects 0.000 claims abstract description 42
- 238000000034 method Methods 0.000 claims abstract description 42
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 36
- 239000004372 Polyvinyl alcohol Substances 0.000 claims abstract description 31
- 230000008569 process Effects 0.000 claims abstract description 27
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims abstract description 23
- GGCZERPQGJTIQP-UHFFFAOYSA-N sodium;9,10-dioxoanthracene-2-sulfonic acid Chemical compound [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-N 0.000 claims abstract description 23
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims abstract description 22
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims abstract description 22
- 229940069328 povidone Drugs 0.000 claims abstract description 19
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 claims abstract description 18
- 235000011187 glycerol Nutrition 0.000 claims abstract description 18
- 238000004132 cross linking Methods 0.000 claims abstract description 17
- 238000006243 chemical reaction Methods 0.000 claims abstract description 12
- 230000001954 sterilising effect Effects 0.000 claims abstract description 12
- 238000004659 sterilization and disinfection Methods 0.000 claims abstract description 12
- 229940068984 polyvinyl alcohol Drugs 0.000 claims abstract description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 48
- 229910052709 silver Inorganic materials 0.000 claims description 41
- 239000004332 silver Substances 0.000 claims description 41
- 229910001868 water Inorganic materials 0.000 claims description 36
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical group [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 claims description 34
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 31
- 239000000203 mixture Substances 0.000 claims description 28
- 238000003756 stirring Methods 0.000 claims description 13
- 229910001961 silver nitrate Inorganic materials 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 239000008240 homogeneous mixture Substances 0.000 claims description 5
- 238000006116 polymerization reaction Methods 0.000 claims description 5
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 4
- 150000001398 aluminium Chemical class 0.000 claims description 4
- 229920001684 low density polyethylene Polymers 0.000 claims description 4
- 239000004702 low-density polyethylene Substances 0.000 claims description 4
- 229940052940 polyvinyl alcohol / povidone Drugs 0.000 claims description 4
- 230000001678 irradiating effect Effects 0.000 claims description 3
- 150000003378 silver Chemical class 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 2
- 239000005022 packaging material Substances 0.000 claims description 2
- 238000009516 primary packaging Methods 0.000 claims description 2
- 238000009517 secondary packaging Methods 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 abstract description 14
- 239000004599 antimicrobial Substances 0.000 abstract description 8
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 41
- 208000027418 Wounds and injury Diseases 0.000 description 29
- 239000000243 solution Substances 0.000 description 27
- 206010052428 Wound Diseases 0.000 description 26
- 230000005855 radiation Effects 0.000 description 17
- 238000012360 testing method Methods 0.000 description 17
- 239000000499 gel Substances 0.000 description 12
- 229920000642 polymer Polymers 0.000 description 12
- 239000000463 material Substances 0.000 description 11
- 150000003254 radicals Chemical class 0.000 description 9
- 239000007864 aqueous solution Substances 0.000 description 8
- 238000010894 electron beam technology Methods 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 6
- 239000003431 cross linking reagent Substances 0.000 description 6
- 230000036571 hydration Effects 0.000 description 6
- 238000006703 hydration reaction Methods 0.000 description 6
- 239000002105 nanoparticle Substances 0.000 description 6
- 230000005540 biological transmission Effects 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000036512 infertility Effects 0.000 description 5
- GUTLYIVDDKVIGB-OUBTZVSYSA-N Cobalt-60 Chemical compound [60Co] GUTLYIVDDKVIGB-OUBTZVSYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 238000010382 chemical cross-linking Methods 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 229920005615 natural polymer Polymers 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- -1 silver ions Chemical class 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 229920001059 synthetic polymer Polymers 0.000 description 4
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 229940072056 alginate Drugs 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 239000003906 humectant Substances 0.000 description 3
- 229920001477 hydrophilic polymer Polymers 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 238000010907 mechanical stirring Methods 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 239000004014 plasticizer Substances 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- FNWXQTYQGUYUSQ-RXSVEWSESA-N (2R)-2-[(1S)-1,2-dihydroxyethyl]-3,4-dihydroxy-2H-furan-5-one silver Chemical compound [Ag].OC[C@H](O)[C@H]1OC(=O)C(O)=C1O FNWXQTYQGUYUSQ-RXSVEWSESA-N 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 2
- 229910017745 AgNP Inorganic materials 0.000 description 2
- 239000004971 Cross linker Substances 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 229910021536 Zeolite Inorganic materials 0.000 description 2
- BRKQRLXNJBPWHN-UHFFFAOYSA-N acetyl 2-hydroxybenzoate;silver Chemical compound [Ag].CC(=O)OC(=O)C1=CC=CC=C1O BRKQRLXNJBPWHN-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 229940113720 aminosalicylate Drugs 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 229920000249 biocompatible polymer Polymers 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 239000008139 complexing agent Substances 0.000 description 2
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229940014144 folate Drugs 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000001095 inductively coupled plasma mass spectrometry Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 231100001081 no carcinogenicity Toxicity 0.000 description 2
- 238000000053 physical method Methods 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000010526 radical polymerization reaction Methods 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 239000011265 semifinished product Substances 0.000 description 2
- NBYLLBXLDOPANK-UHFFFAOYSA-M silver 2-carboxyphenolate hydrate Chemical compound C1=CC=C(C(=C1)C(=O)O)[O-].O.[Ag+] NBYLLBXLDOPANK-UHFFFAOYSA-M 0.000 description 2
- NDVLTYZPCACLMA-UHFFFAOYSA-N silver oxide Chemical compound [O-2].[Ag+].[Ag+] NDVLTYZPCACLMA-UHFFFAOYSA-N 0.000 description 2
- NEMJXQHXQWLYDM-JJKGCWMISA-M silver;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ag+].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O NEMJXQHXQWLYDM-JJKGCWMISA-M 0.000 description 2
- MNMYRUHURLPFQW-UHFFFAOYSA-M silver;dodecanoate Chemical compound [Ag+].CCCCCCCCCCCC([O-])=O MNMYRUHURLPFQW-UHFFFAOYSA-M 0.000 description 2
- RZTYEUCBTNJJIW-UHFFFAOYSA-K silver;zirconium(4+);phosphate Chemical compound [Zr+4].[Ag+].[O-]P([O-])([O-])=O RZTYEUCBTNJJIW-UHFFFAOYSA-K 0.000 description 2
- 231100000444 skin lesion Toxicity 0.000 description 2
- 206010040882 skin lesion Diseases 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- 239000010457 zeolite Substances 0.000 description 2
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 1
- ZXSQEZNORDWBGZ-UHFFFAOYSA-N 1,3-dihydropyrrolo[2,3-b]pyridin-2-one Chemical compound C1=CN=C2NC(=O)CC2=C1 ZXSQEZNORDWBGZ-UHFFFAOYSA-N 0.000 description 1
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- SBKRTALNRRAOJP-BWSIXKJUSA-N N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methylheptanamide (6S)-N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methyloctanamide sulfuric acid Polymers OS(O)(=O)=O.CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O.CC[C@H](C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O SBKRTALNRRAOJP-BWSIXKJUSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 229920003072 Plasdone™ povidone Polymers 0.000 description 1
- 108010093965 Polymyxin B Proteins 0.000 description 1
- 229920003081 Povidone K 30 Polymers 0.000 description 1
- ZSILVJLXKHGNPL-UHFFFAOYSA-L S(=S)(=O)([O-])[O-].[Ag+2] Chemical compound S(=S)(=O)([O-])[O-].[Ag+2] ZSILVJLXKHGNPL-UHFFFAOYSA-L 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- RZESOXIJGKVAAX-UHFFFAOYSA-L [Ag++].[O-]C(=O)CCC([O-])=O Chemical compound [Ag++].[O-]C(=O)CCC([O-])=O RZESOXIJGKVAAX-UHFFFAOYSA-L 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 229910052946 acanthite Inorganic materials 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 125000005037 alkyl phenyl group Chemical group 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000002358 autolytic effect Effects 0.000 description 1
- 210000004666 bacterial spore Anatomy 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 1
- 238000011021 bench scale process Methods 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000035597 cooling sensation Effects 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000001804 debridement Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229940014041 hyaluronate Drugs 0.000 description 1
- WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 description 1
- 229940091173 hydantoin Drugs 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000000242 nostrum Substances 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229960003548 polymyxin b sulfate Drugs 0.000 description 1
- USHAGKDGDHPEEY-UHFFFAOYSA-L potassium persulfate Chemical compound [K+].[K+].[O-]S(=O)(=O)OOS([O-])(=O)=O USHAGKDGDHPEEY-UHFFFAOYSA-L 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 238000011112 process operation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- LKZMBDSASOBTPN-UHFFFAOYSA-L silver carbonate Substances [Ag].[O-]C([O-])=O LKZMBDSASOBTPN-UHFFFAOYSA-L 0.000 description 1
- 229910001958 silver carbonate Inorganic materials 0.000 description 1
- YSVXTGDPTJIEIX-UHFFFAOYSA-M silver iodate Chemical compound [Ag+].[O-]I(=O)=O YSVXTGDPTJIEIX-UHFFFAOYSA-M 0.000 description 1
- XNGYKPINNDWGGF-UHFFFAOYSA-L silver oxalate Chemical compound [Ag+].[Ag+].[O-]C(=O)C([O-])=O XNGYKPINNDWGGF-UHFFFAOYSA-L 0.000 description 1
- 229910001923 silver oxide Inorganic materials 0.000 description 1
- FJOLTQXXWSRAIX-UHFFFAOYSA-K silver phosphate Chemical compound [Ag+].[Ag+].[Ag+].[O-]P([O-])([O-])=O FJOLTQXXWSRAIX-UHFFFAOYSA-K 0.000 description 1
- 229940019931 silver phosphate Drugs 0.000 description 1
- 229910000161 silver phosphate Inorganic materials 0.000 description 1
- YPNVIBVEFVRZPJ-UHFFFAOYSA-L silver sulfate Chemical compound [Ag+].[Ag+].[O-]S([O-])(=O)=O YPNVIBVEFVRZPJ-UHFFFAOYSA-L 0.000 description 1
- 229910000367 silver sulfate Inorganic materials 0.000 description 1
- 229940056910 silver sulfide Drugs 0.000 description 1
- XUARKZBEFFVFRG-UHFFFAOYSA-N silver sulfide Chemical compound [S-2].[Ag+].[Ag+] XUARKZBEFFVFRG-UHFFFAOYSA-N 0.000 description 1
- RHUVFRWZKMEWNS-UHFFFAOYSA-M silver thiocyanate Chemical compound [Ag+].[S-]C#N RHUVFRWZKMEWNS-UHFFFAOYSA-M 0.000 description 1
- IENRGOATEFXJHQ-UHFFFAOYSA-M silver;2-sulfanylacetate Chemical compound [Ag+].[O-]C(=O)CS IENRGOATEFXJHQ-UHFFFAOYSA-M 0.000 description 1
- CLDWGXZGFUNWKB-UHFFFAOYSA-M silver;benzoate Chemical compound [Ag+].[O-]C(=O)C1=CC=CC=C1 CLDWGXZGFUNWKB-UHFFFAOYSA-M 0.000 description 1
- LTYHQUJGIQUHMS-UHFFFAOYSA-M silver;hexadecanoate Chemical compound [Ag+].CCCCCCCCCCCCCCCC([O-])=O LTYHQUJGIQUHMS-UHFFFAOYSA-M 0.000 description 1
- UKHWJBVVWVYFEY-UHFFFAOYSA-M silver;hydroxide Chemical compound [OH-].[Ag+] UKHWJBVVWVYFEY-UHFFFAOYSA-M 0.000 description 1
- ORYURPRSXLUCSS-UHFFFAOYSA-M silver;octadecanoate Chemical compound [Ag+].CCCCCCCCCCCCCCCCCC([O-])=O ORYURPRSXLUCSS-UHFFFAOYSA-M 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000013190 sterility testing Methods 0.000 description 1
- 238000012414 sterilization procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000033772 system development Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000010977 unit operation Methods 0.000 description 1
- 238000009849 vacuum degassing Methods 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/60—Liquid-swellable gel-forming materials, e.g. super-absorbents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0071—Plasticisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/008—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/102—Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
- A61L2300/104—Silver, e.g. silver sulfadiazine
Definitions
- the present invention relates to an antimicrobial hydrogel comprising polyvinyl alcohol (PVA), povidone, glycerine and silver salt.
- PVA polyvinyl alcohol
- povidone povidone
- glycerine glycerine
- silver salt silver salt
- the present invention specifically relates to a simple process for the preparation of efficient antimicrobial hydrogel, wherein the process comprising steps of crosslinking, conversion of silver salt into silver nanoparticles and sterilization of solution in pouch by using of gamma irradiation.
- Burn injuries are critical condition and difficult to manage, due to significant loss of fluids, tissue damage and results deep wounds. Further, it may hinder the important functions of skin. The compromised skin cannot prevent the microbial invasion which leads to infectious wounds. According to WHO, more than 30,000 deaths occur in each year as a consequence of different types of burns caused by chemicals, radiation and electricity. In the case of burn injuries, appropriate treatment should be given to increase the survival chances of patient.
- wound dressing should provide moist environment, acts as a barrier to prevent invasion of contaminants, provide antimicrobial action, promote wound healing, application and removal should be easy, non-toxic and non-allergic.
- Hydrogels are class of wound dressings applied on injuries/wounds associated with burns. Hydrogels are stabilized macro molecular networks by means of physical or chemical interactions among the polymer chains. Due to hydrophilic nature and polymeric network structure, which are able to retain large amounts of water in their mesh structure.
- Polymeric hydrogels importance has increased significantly for the treatment of burns and other skin lesions. In case of burns, cleaning under running water will not provide enough satisfaction. Application of hydrogels onto burn area is the best way to provide coolness and in order to minimize the extent of damage and reduce pain.
- the drawbacks associated with conventional antimicrobial gel/ointment formulations for burn treatment include requirement of applicator to deliver medicament, which may liquefy or soften after some time of application and migrate or move away from injured area.
- the hydrogel gives pleasant cooling sensation, soothe pain, absorb wound exudate, non-sticky to wound, easy of removal/replacement without any damage, are sterile and acts as barrier, Further
- the hydrogel would reside on the required region for a long time, resulting in better patient compliance and therapeutic effects.
- hydrogel transparency allows instant monitoring of healing process.
- CN 102698313 discloses nano silver antimicrobial hydrogels and their preparation, wherein the antimicrobial hydrogel contain a natural polymer or a derivative thereof, a synthetic polymer, nano silver and water containing silver ions.
- This patent also discloses the process for the preparation, wherein process comprising a powder of natural / synthetic polymer was mixed with an aqueous silver nitrate solution and stirred uniformly with a defoaming stirrer to obtain a solid content of 10% aqueous solution. The aqueous solution was filled into the test tube; the bubbles were removed, sealed and then irradiated with 60 Co gamma rays for 30 kGy to obtain nano silver antibacterial hydrogel.
- CN 103623453 discloses a process for preparing a silver ion hydrogel dressing, said process comprising 15g of polyvinyl alcohol and 85g water can be heated investment, stirring and vacuum degassing the reactor, the temperature and stir until completely dissolved, the feed liquid was cooled to room temperature to obtain an aqueous solution of a hydrophilic polymer; system hydrophilic polymer solution was injected into the mold, the upper surface is covered from the film, semi-finished products to obtain hydrogel material; the prepared hydrogel material semi-finished products by cobalt 60 radioactive sources of high-energy radiation dose of 30kgy radiation, to prepare a hydrogel material; hydrogel material is immersed in the silver ion concentration of 0.05% by weight of the silver nitrate solution, the hydrogel material weight silver ion content of 0.005%, the silver ions to prepare a hydrogel dressing. It also discloses the hydrogel is prepared by using high energy radiation dose of 10-100 kGy a Cobalt 60 radioactive source.
- KR 101242574 discloses a process for preparing hydrogel dressing for wound care comprising biocompatible polymer and nanoparticles involves following steps. 1. Biocompatible polymer (PVA) is added to purified water to obtain aqueous solution. 2. Pour the aqueous solution of step 1 into the tray and moulded to the hydration gel of the sheet form. 3. Formed hydration gel of step 2 is cross-linked by irradiating with radiation. 4. Formed crosslinked hydration gel of step 3 is dipped into silver nitrate aqueous solution to form nanosilver particles within the hydration gel. 5. Wrapping the hydration gel of step 4 and sterilization is used in manufacturing hydration gel. It also discloses dose of radiation is preferably 2-200 kGy.
- WO 2007/002705 discloses process of making hydrogel having antimicrobial properties comprising polyvinyl alcohol as hydrogel-forming polymer and silver antimicrobial agent. It also discloses cross linking of polyvinyl alcohol and water to form hydrogel using gamma radiations. Then the silver flakes were dispersed into a hydrogel, and the composite was crosslinked using an electron-beam, die cut and packaged.
- WO 2012/005759 discloses hydrogel is being formed in situ on the wound surface using a free radical initiation system or redox reaction.
- the composition includes a PVA macromer that can quickly crosslink to form a hydrogel dressing on a wound, aqueous media, redox components, stabilizers for the redox components, and one or more antimicrobial agents preferable silver salts, and may include additives such as an absorbent, and other active agents.
- US 2013/0052257 Al discloses antimicrobial hydrogel wound dressing using polyvinyl alcohol (PVA), polyvinyl pyrrolidone (PVP) and agar, all components were dissolved in distilled water, the solution mixture was crosslinked by gamma radiation.
- PVA polyvinyl alcohol
- PVP polyvinyl pyrrolidone
- the prepared hydrogel Prior to crosslinking by gamma radiation, an effective amount of a pair of antibiotics, polymyxin B sulfate and neomycin are added to the solution at room temperature.
- the prepared hydrogel has good mechanical strength, water absorption capability and antimicrobial action against various types of microorganisms.
- PVA aqueous solutions were obtained by dissolving 10 g of PVA in 100 ml of distilled and deionized water at 90°C for 2 h, under mechanical stirring.
- 10 g of PVA was dissolved in 70 ml of distilled and deionized water at 90°C C for 2 h, under mechanical stirring, and the AgNO 3 solutions were obtained by dissolving the correct amount of AgNO 3 in 30 ml of distilled and deionized water at room temperature in the dark, under magnetic stirring for 2 h.
- the AgNO 3 solutions were mixed with the PVA solutions under mechanical stirring, in the dark, at room temperature for 30 min, resulting in solutions containing 10 g of PVA and 0.00%, 0.25% or 0.50% AgNO 3 (relative to the weight of the polymer), in 100 ml H 2 O.
- J Polym Res (2012) 19:9835 discloses a series of polyvinyl alcohol/polyvinyl pyrrolidone based hydrogels containing the silver nanoparticles. This article also discloses preparation of different hydrogel compositions by gamma irradiation.
- PVA based hydrogels have gained great importance due to its low toxicity, non-carcinogenicity and high biocompatibility.
- various methods have been reported for crosslinking of PVA, including chemical methods using crosslinking agents, physical methods using complexing agent and radiation methods using ⁇ -radiation, electron beams, or ultraviolet light (Hennink and Nostrum, 2002; Elbadawy et al, 2015).
- All the prior art references shows polymeric hydrogels are used significantly for the treatment of burns and other skin lesions, the process for preparation of silver ion hydrogel dressing, hydrogel dressing for wound care, hydrogel wound dressing, hydrogel having antimicrobial properties, polyvinyl alcohol nano- silver hydrogel wound dressing, antimicrobial wound dressing.
- an antimicrobial hydrogel dressing comprising PVA, povidone, glycerine and silver salt which is prepared by gamma irradiation for crosslinking, conversion of silver salt into silver nanoparticles and sterilization which limits number of unit operations by reducing process time and process cost.
- the objective of the present invention is to provide an antimicrobial hydrogel comprising polyvinyl alcohol, povidone, glycerine and silver salt.
- Another objective of the present invention is to provide a simple effective process for the preparation of antimicrobial hydrogel, wherein process comprises crosslinking, conversion of silver salt into silver nanoparticles and sterilization using gamma irradiation in single step.
- One embodiment of the present invention provides antimicrobial hydrogel comprising polyvinyl alcohol, povidone or povidone derivatives, glycerine and silver salts.
- Another embodiment of the present invention provides antimicrobial hydrogel comprising polyvinyl alcohol as matrix hydrogel base material, povidone or povidone derivatives as a stabilizer to prevent nanoparticle aggregation, glycerine as humectant and plasticizer and silver salt as antimicrobial precursor.
- Another embodiment of the present invention provides antimicrobial hydrogel comprising polyvinyl alcohol, povidone or povidone derivatives, glycerine, wherein the silver salt converts into silver nanoparticles and soluble silver during process operations.
- Another embodiment of the present invention provides a process for the preparation of antimicrobial hydrogel comprising polyvinyl alcohol as matrix hydrogel base material, povidone as stabilizer to prevent nanoparticle aggregation, glycerine as humectant and plasticizer and silver salt as antimicrobial precursor.
- Another embodiment of the present invention provides a process for the preparation of antimicrobial hydrogel, wherein the process comprising crosslinking, conversion of silver salt into silver nanoparticles and sterilization of hydrogel solution in pouch using gamma irradiation in single step process which reduces process time and process cost.
- Another embodiment of the present invention provides a process for preparing antimicrobial hydrogel, wherein the process comprising steps of: a) dissolving polyvinyl alcohol in water and stirring at 60°C to obtain the polyvinyl alcohol solution,
- the packaging material should withstand gamma irradiation
- Hydrogel is a type of hydrophilic polymer three-dimensional network that swells in water but does not dissolve in water and retains a certain amount of water (more than 20%) inside its structure. In addition to its good biocompatibility, it also has a high water permeability, a certain degree of strength, the surface is similar to the soft tissue of the organism, these features make the hydrogel can be used as biological materials. Hydrogel has excellent physical and chemical properties and biological properties can control the drug release, and bioadhesive, biocompatible and biodegradable properties, has been used for slow release, pulse release, trigger release and other new to drug system development.
- Hydrogel wound dressings provide several advantages over conventional wound dressings.
- Hydrogel polymers are hydrophilic, so that they absorb water, keeping the environment moist, thereby promoting healing, rehydrating dead tissues, and enhancing autolytic debridement.
- Hydrogel dressings are often cool on the surface of the wound, helping to relieve pain. By absorbing water, hydrogels permit the transport of drugs through the network of crosslinked polymer.
- Preparation of hydrogels using natural polysaccharides often prone to degradation of polysaccharide over time, result in shortening of hydrogel dressing life time and it may allow the growth of microorganisms.
- Preparation of hydrogels using synthetic or semisynthetic polymers is relatively better to control and optimize the process parameters.
- PVA based hydrogels have gained great importance due to its low toxicity, non-carcinogenicity and high biocompatibility.
- methods that have been reported for crosslinking of PVA including chemical methods using crosslinking agents, physical methods using complexing agent and radiation methods using ⁇ -radiation, electron beams, or ultraviolet light.
- Hydrogel transparency, integrity and flexibility which may depend on the crosslink density of the polymer network, molecular weight of polymer and gamma irradiation dose.
- Hydrogels offer a useful starting point to engineer antimicrobial materials. They are a class of highly hydrated biomaterial, usually produced from natural or synthetic polymers. Polysaccharides such as alginate, dextran, and chitosan, along with the proteins gelatin and fibrin, are examples of natural polymers that form well- studied hydrogels. Poly (vinyl alcohol) (PVA), polyethylene oxide (PEO), and poly (acrylic acid) (PA A) are examples of hydrogel-forming synthetic polymers. Preferably Poly (vinyl alcohol) (PVA).
- the concentration of the polyvinyl alcohol is 5% to 20% w/w, preferably 10% to 15% w/w, most preferably 12.5%.
- Polyvinyl alcohol used in the present invention has a molecular weight of at least 10,000.
- the polyvinyl alcohols may have a molecular weight of up to 1,000,000.
- the polyvinyl alcohols have a molecular weight of 31,000 to about 1,90,000 g/mol, especially preferably up to approximately about 1,60,000 g/mol.
- Silver based compounds are already proven to be effective antimicrobial agents against various types of microorganisms. Compared to other metals, silver is less toxic to mammalian cells and is being used in numerous biomedical applications including wound dressings to treat infections. Silver is active in charged (Ag + ) and uncharged (Ag) form. The uncharged form of silver is available in nanoparticle form.
- the ionic form of silver has inherent antimicrobial effect by disrupting bacterial cell wall, in the membranes and nucleic acids of bacterial cell.
- Silver nanoparticles also has been shown to effective antiseptic and multi-level antimicrobial action. Although the antimicrobial action of AgNP is well described, their mechanism of action is not clear so far.
- Silver salt is selected from but not limited to silver thiocyanate, silver oxide, silver sulfate, silver alkyl carboxylate (Q to C 12 ), silver aryl sulfonate (Q to C 4 alkyl phenyl), silver nitrate, silver carbonate, silver sulfide, silver phosphoranilide, silver phosphate, silver hydroxide, silver hyaluronate, silver benzoate, silver tartarate, silver thiosulfate complex, silver laurate, silver zeolite, silver zirconium phosphate, silver alginate, silver ascorbate, silver folate, silver gluconate, silver salicylate, silver para amino benzoate, silver para amino salicylate, silver acetyl salicylate, silver EDTA, silver laurate, silver zeolite, silver zirconium phosphate, silver alginate, silver ascorbate, silver folate, silver iodate, silver oxalate, silver palmitate, silver
- the concentration of silver salt used in the present invention is about 0.001% - 0.1% w/w, preferably 0.002 % (w/w).
- Povidone or its derivatives are used as a stabilizer to prevent nanoparticle aggregation and Povidone or its derivatives are selected from plasdone S630, povidone 90, povidone K30 and/ or mixture thereof.
- the concentration of Povidone or its derivatives used in the present invention is about 0.25 % to about 1% (w/w), preferably 0.5 % (w/w).
- Glycerine is used as humectant and plasticizer and the concentration of glycerine is about 0.1 % to about 0.5% (w/w). preferably 0.25 % (w/w).
- Purified water is used as a solvent in the concentration of about 80-95% w/v.
- hydrogel dressings play a significant role.
- Hydrogels are polymer network system which mimic biological tissues because of presence of high amounts of water and flexibility.
- hydrogel dressing may cause microbial infection in wound area is due to moist environment. Hence, it is necessary to develop sterile anti- microbial hydrogel dressing.
- hydrogel Use of free radical initiators for the formation of hydrogel may contain residual amounts in the final product, which may be harmful and toxic. Further, the formed hydrogel may not be sterile and have insufficient mechanical properties.
- Gamma and electron beam polymerization involves high energy electromagnetic irradiation as crosslinker. These high energy radiations can crosslink water-soluble monomer or polymer chain ends without the addition of a crosslinker.
- aqueous solutions of monomers are polymerized to form a hydrogel.
- Gamma and electron beam polymerizations also involves the initiation, propagation, and termination steps as in the free radical polymerization. Hydroxyl radicals are formed and initiate free radical polymerization among the vinyl monomers which propagate in a rapid chain addition fashion. The hydrogel is finally formed once the network reaches the critical gelation point.
- This process has an advantage over other crosslinking methods since it can be performed at room temperature and in physiological pH without using toxic and hard to remove crosslinking agents such as potassium persulfate.
- Chemical cross-linking is a highly versatile method to improve the mechanical property of the hydrogels.
- cross-linking agents are often toxic compounds and not environmental friendly. They give unwanted reactions with the bioactive substances present in the hydrogel matrix. The adverse effects of chemical cross-linking can be avoided by the process of physical cross linking using radiation or electron beam method.
- gamma radiation method an advantage of gamma radiation method are noticed in that the method can cause crosslinking as well as sterilization of the materials through container in which the materials are completely enclosed and besides the method is effective for bacterial spores high in heat resistance bacteria. Further, gamma sterilization method is considered to have high reliability in sterilization. Hydrogels prepared by gamma radiation method does not require operation for removal of residual toxin, unlike hydrogels prepared using chemical crosslinking agents may contain unreacted chemical crosslinking agent, which may be toxic and further requires purification or neutralization or sterilization procedures.
- the present invention relates to preparation of sterile antimicrobial hydrogel dressing to treat burns and wounds.
- Use of one step gamma radiation can cause crosslinking of polyvinyl alcohol to form hydrogel with simultaneous reduction of silver nitrate to silver nanoparticles for effective antimicrobial action.
- the antimicrobial hydrogel dressing is being sterilized during gamma irradiation.
- PH is PVA long chain and P is PVA short chain
- PVA crosslinks There may be further degradation of PVA crosslinks due to oxygen evolution but other additives in PVA hydrogel protect polymer against degradation by radical transfer and recombination of radicals produced from irradiation of water.
- PVA mixed with silver salt the ionic silver is attracted by the chains' hydroxyl groups. After gamma-irradiation, silver is reduced, and nanoparticles are formed close to the OH- groups, remaining entrapped in the PVA network.
- the PVA chains can be cross-linked when irradiated. Formulations were developed using various concentrations of PVA and AgNO 3 exposed to different gamma irradiation doses.
- compositions resulted in stable and homogenous hydrogels, which are evaluated for their description, thickness, water absorption capacity, percentage elongation, tensile strength, silver content and sterility.
- Example 1 describes the nature of the invention and are given only for the purpose of illustrating the present invention in more detail and are not limitative and relate to solutions which have been particularly effective on a bench scale.
- Example 1 describes the nature of the invention and are given only for the purpose of illustrating the present invention in more detail and are not limitative and relate to solutions which have been particularly effective on a bench scale.
- Povidone was added to polyvinyl alcohol solution under stirring at same temperature. The obtained solution was allowed to cool down to room temperature.
- Glycerine and silver nitrate were added to obtained polyvinyl alcohol - povidone solution mixture under stirring at room temperature to obtain homogenous mixture.
- the obtained homogenous solution was filled into LDPE pouches of predetermined fill weight.
- the filled pouches were irradiated with gamma irradiation by 60 Co source at the doses of 25 kGy for crosslinking of PVA and conversion of silver salt into silver nanoparticles along with sterilization.
- Hydrogel sample was placed or applied on skin and checked for whether sample was adhering to skin or not.
- Tensile strength Tensile strength of hydrogel samples were measured using universal testing machine.
- Water vapour transmission rate is a measure of the passage of water vapour through the material. It is also known as moisture vapour transmission rate (MVTR). It is the mass of water vapour transmitted through a unit area in a unit time under specified conditions of temperature and humidity.
- Silver content in hydrogel sample was measured using Inductively coupled plasma mass spectrometry (ICP-MS).
- Sterility test Sterility testing was performed according to USP general chapter ⁇ 71 >.
- Antimicrobial effectiveness testing Antimicrobial effectiveness was performed for optimized formulations with silver content in the range of 0.001% to 0.1%. The testing was performed according to USP General Chapter (51).
- Bacterial Endotoxin Test Bacterial Endotoxin Test was performed for optimized formulation. The testing was performed according to USP General Chapter ⁇ 85 >.
- Endotoxin Complies - hydrogel
- Endotoxin Complies - hydrogel
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Materials Engineering (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dispersion Chemistry (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
Abstract
La présente invention concerne un hydrogel antimicrobien comprenant de l'alcool polyvinylique (PVA), de la povidone, de la glycérine et du sel d'argent. La présente invention concerne spécifiquement un procédé simple pour la préparation d'un hydrogel antimicrobien efficace, le procédé comprenant des étapes de réticulation, de conversion de sel d'argent en nanoparticules d'argent et de stérilisation de solution dans un sachet au moyen d'une irradiation gamma.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201741008595 | 2017-03-11 | ||
IN201741008595 | 2017-03-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018167623A1 true WO2018167623A1 (fr) | 2018-09-20 |
Family
ID=63523384
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2018/051586 WO2018167623A1 (fr) | 2017-03-11 | 2018-03-10 | Procédé de préparation d'hydrogel antimicrobien |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2018167623A1 (fr) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111303678A (zh) * | 2020-03-02 | 2020-06-19 | 关圣睿 | 一种装修材料用负离子粉及其制备方法和应用 |
CN113861452A (zh) * | 2021-11-02 | 2021-12-31 | 长春中医药大学 | 一种导电抗菌复合水凝胶及其制备方法、应用 |
CN114437371A (zh) * | 2022-01-14 | 2022-05-06 | 陕西科技大学 | 一种基于双交联机制的酪蛋白基纳米杂化水凝胶的制备方法 |
CN114767923A (zh) * | 2022-03-24 | 2022-07-22 | 金发科技股份有限公司 | 一种复合水凝胶载银长效抗菌敷料及其制备方法和应用 |
WO2022264149A1 (fr) * | 2021-06-16 | 2022-12-22 | Bar-Ilan University | Hydrogels de pva/pvp biodégradables, leurs utilisations et leur préparation |
CN115777725A (zh) * | 2022-12-02 | 2023-03-14 | 山西益鑫泰生物科技有限公司 | 一种纳米银消毒剂及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102698313A (zh) * | 2012-01-11 | 2012-10-03 | 北京大学 | 一种纳米银抗菌水凝胶及其制备方法 |
WO2012151438A1 (fr) * | 2011-05-05 | 2012-11-08 | Celacare Technologies, Llc | Composition antimicrobienne d'hydrogel à base d'argent pour traitement de brûlures et de plaies |
EP2991658A1 (fr) * | 2013-05-02 | 2016-03-09 | Medical Technology Research Inc. | Compositions antimicrobiennes et leurs procédés de fabrication |
-
2018
- 2018-03-10 WO PCT/IB2018/051586 patent/WO2018167623A1/fr active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012151438A1 (fr) * | 2011-05-05 | 2012-11-08 | Celacare Technologies, Llc | Composition antimicrobienne d'hydrogel à base d'argent pour traitement de brûlures et de plaies |
CN102698313A (zh) * | 2012-01-11 | 2012-10-03 | 北京大学 | 一种纳米银抗菌水凝胶及其制备方法 |
EP2991658A1 (fr) * | 2013-05-02 | 2016-03-09 | Medical Technology Research Inc. | Compositions antimicrobiennes et leurs procédés de fabrication |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111303678A (zh) * | 2020-03-02 | 2020-06-19 | 关圣睿 | 一种装修材料用负离子粉及其制备方法和应用 |
WO2022264149A1 (fr) * | 2021-06-16 | 2022-12-22 | Bar-Ilan University | Hydrogels de pva/pvp biodégradables, leurs utilisations et leur préparation |
CN113861452A (zh) * | 2021-11-02 | 2021-12-31 | 长春中医药大学 | 一种导电抗菌复合水凝胶及其制备方法、应用 |
CN114437371A (zh) * | 2022-01-14 | 2022-05-06 | 陕西科技大学 | 一种基于双交联机制的酪蛋白基纳米杂化水凝胶的制备方法 |
CN114437371B (zh) * | 2022-01-14 | 2023-09-05 | 陕西科技大学 | 一种基于双交联机制的酪蛋白基纳米杂化水凝胶的制备方法 |
CN114767923A (zh) * | 2022-03-24 | 2022-07-22 | 金发科技股份有限公司 | 一种复合水凝胶载银长效抗菌敷料及其制备方法和应用 |
CN115777725A (zh) * | 2022-12-02 | 2023-03-14 | 山西益鑫泰生物科技有限公司 | 一种纳米银消毒剂及其制备方法 |
CN115777725B (zh) * | 2022-12-02 | 2024-01-26 | 山西益鑫泰生物科技有限公司 | 一种纳米银消毒剂及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2018167623A1 (fr) | Procédé de préparation d'hydrogel antimicrobien | |
Rosiak et al. | Medical applications of radiation formed hydrogels | |
Mozalewska et al. | Chitosan-containing hydrogel wound dressings prepared by radiation technique | |
CN102698313B (zh) | 一种纳米银抗菌水凝胶及其制备方法 | |
JP3947391B2 (ja) | 橋かけ構造を有するキチン誘導体及び/又はキトサン誘導体の製造方法 | |
Singh et al. | Sterculia crosslinked PVA and PVA-poly (AAm) hydrogel wound dressings for slow drug delivery: mechanical, mucoadhesive, biocompatible and permeability properties | |
Razzak et al. | Irradiation of polyvinyl alcohol and polyvinyl pyrrolidone blended hydrogel for wound dressing | |
Bento et al. | A review of conventional and emerging technologies for hydrogels sterilization | |
US9050392B2 (en) | Hydrogel and biomedical applications thereof | |
CA2653200A1 (fr) | Agents anti-reticulation et procedes permettant de bloquer la reticulation de preparations d'hydrogel injectables | |
De Silva et al. | Development of a PVP/kappa-carrageenan/PEG hydrogel dressing for wound healing applications in Sri Lanka | |
WO2001030407A1 (fr) | Procede de preparation d'hydrogels destines au traitement de brulures et de blessures | |
KR101242574B1 (ko) | 은 나노입자를 함유하는 상처치료용 수화겔 및 이의 제조방법 | |
Roy et al. | PVP-based hydrogels: Synthesis, properties and applications | |
US20120107369A1 (en) | Polymers and Hydrogels | |
KR102264090B1 (ko) | 금속-유기프레임워크 포함 항균 하이드로겔 | |
Lukitowati et al. | Water Absorption of Chitosan, Collagen, and Chitosan/Collagen Blend Membranes Exposed to Gamma-Ray Irradiation: Water Absorption of the Membranes Exposed to Irradiation | |
KR101109146B1 (ko) | 베타글루칸을 함유한 상처치료용 수화겔 및 이의 제조방법 | |
WO2016155749A1 (fr) | Produit hémostatique et cicatrisant | |
US20210178026A1 (en) | Radiation sterilized hydrogels, medical devices including radiation sterilized hydrogels and methods of making the same | |
KR101303284B1 (ko) | 히알루론산과 콘드로이틴 설페이트를 함유한 수화겔 및 이의 제조방법 | |
CZ302380B6 (cs) | Suchá substance hydrogelu pro krytí ran a zpusob její prípravy | |
WO2010067378A2 (fr) | Composition d'hydrogel | |
KR20010086864A (ko) | 방사선 이용 수화겔 드레싱 제조방법 | |
KR101325680B1 (ko) | 메트로니다졸을 함유한 수화겔 및 이의 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18767867 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 18767867 Country of ref document: EP Kind code of ref document: A1 |